aTyr Pharma (ATYR) Competitors $5.83 +0.28 (+5.05%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$5.87 +0.04 (+0.67%) As of 07/25/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATYR vs. KNSA, TWST, CNTA, BEAM, CGON, DNLI, HRMY, IRON, MESO, and BLTEShould you be buying aTyr Pharma stock or one of its competitors? The main competitors of aTyr Pharma include Kiniksa Pharmaceuticals International (KNSA), Twist Bioscience (TWST), Centessa Pharmaceuticals (CNTA), Beam Therapeutics (BEAM), CG Oncology (CGON), Denali Therapeutics (DNLI), Harmony Biosciences (HRMY), Disc Medicine (IRON), Mesoblast (MESO), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry. aTyr Pharma vs. Its Competitors Kiniksa Pharmaceuticals International Twist Bioscience Centessa Pharmaceuticals Beam Therapeutics CG Oncology Denali Therapeutics Harmony Biosciences Disc Medicine Mesoblast Belite Bio Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations. Which has more risk & volatility, KNSA or ATYR? Kiniksa Pharmaceuticals International has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Does the media refer more to KNSA or ATYR? In the previous week, Kiniksa Pharmaceuticals International had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 9 mentions for Kiniksa Pharmaceuticals International and 8 mentions for aTyr Pharma. Kiniksa Pharmaceuticals International's average media sentiment score of 0.64 beat aTyr Pharma's score of 0.62 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive aTyr Pharma 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, KNSA or ATYR? Kiniksa Pharmaceuticals International has higher revenue and earnings than aTyr Pharma. Kiniksa Pharmaceuticals International is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals International$481.17M3.99-$43.19M-$0.25-105.32aTyr PharmaN/AN/A-$64.02M-$0.81-7.20 Is KNSA or ATYR more profitable? aTyr Pharma has a net margin of 0.00% compared to Kiniksa Pharmaceuticals International's net margin of -3.52%. Kiniksa Pharmaceuticals International's return on equity of -3.83% beat aTyr Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals International-3.52% -3.83% -2.98% aTyr Pharma N/A -87.09%-64.77% Do analysts prefer KNSA or ATYR? Kiniksa Pharmaceuticals International presently has a consensus target price of $39.67, indicating a potential upside of 50.65%. aTyr Pharma has a consensus target price of $20.20, indicating a potential upside of 246.48%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Kiniksa Pharmaceuticals International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals International 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00aTyr Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Do insiders and institutionals believe in KNSA or ATYR? 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 53.5% of Kiniksa Pharmaceuticals International shares are held by insiders. Comparatively, 3.7% of aTyr Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryKiniksa Pharmaceuticals International beats aTyr Pharma on 8 of the 15 factors compared between the two stocks. Get aTyr Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATYR vs. The Competition Export to ExcelMetricaTyr PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$518.89M$3.05B$5.70B$9.50BDividend YieldN/A2.37%4.58%4.00%P/E Ratio-7.2021.3228.3920.08Price / SalesN/A280.80430.0899.95Price / CashN/A42.7636.2258.56Price / Book7.028.378.675.88Net Income-$64.02M-$55.19M$3.25B$258.89M7 Day Performance-2.67%5.86%4.30%3.70%1 Month Performance9.79%17.29%10.57%11.71%1 Year Performance162.61%4.39%35.68%17.98% aTyr Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATYRaTyr Pharma2.1562 of 5 stars$5.83+5.0%$20.20+246.5%+161.4%$518.89MN/A-7.2053News CoverageGap UpKNSAKiniksa Pharmaceuticals International3.4549 of 5 stars$28.42-2.1%$39.67+39.6%+1.6%$2.12B$423.24M-113.68220News CoverageTWSTTwist Bioscience4.3618 of 5 stars$34.77-1.1%$50.40+45.0%-37.4%$2.11B$312.97M-10.70990News CoveragePositive NewsCNTACentessa Pharmaceuticals3.3124 of 5 stars$16.06+2.4%$28.10+75.0%+49.8%$2.10B$6.85M-8.87200News CoverageInsider TradeBEAMBeam Therapeutics2.259 of 5 stars$21.03+1.3%$48.75+131.8%-32.5%$2.09B$63.52M-4.56510Analyst RevisionCGONCG Oncology2.6049 of 5 stars$26.90+0.6%$55.30+105.6%-20.9%$2.04B$1.14M-17.8161Positive NewsDNLIDenali Therapeutics4.2613 of 5 stars$13.83-1.2%$33.71+143.8%-43.3%$2.03B$330.53M-5.18430News CoveragePositive NewsUpcoming EarningsHRMYHarmony Biosciences4.7915 of 5 stars$35.25+0.1%$51.00+44.7%+12.7%$2.02B$714.73M13.45200Positive NewsAnalyst RevisionIRONDisc Medicine3.3774 of 5 stars$59.38+2.8%$95.73+61.2%+38.0%$2.00BN/A-15.1530News CoverageInsider TradeGap UpMESOMesoblast1.497 of 5 stars$14.65-6.2%$18.00+22.9%+120.5%$2.00B$5.90M0.0080Upcoming EarningsGap DownBLTEBelite Bio1.7702 of 5 stars$61.30+0.6%$96.67+57.7%+28.7%$1.94BN/A-45.0710 Related Companies and Tools Related Companies Kiniksa Pharmaceuticals International Alternatives Twist Bioscience Alternatives Centessa Pharmaceuticals Alternatives Beam Therapeutics Alternatives CG Oncology Alternatives Denali Therapeutics Alternatives Harmony Biosciences Alternatives Disc Medicine Alternatives Mesoblast Alternatives Belite Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATYR) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
